192 filings
Page 2 of 10
6-K
jkb0dvpte2s 3g9gk96
9 Jan 23
Affimed Reports on Corporate Progress and Provides
6:45am
6-K
q4hbguo73 p3tgde
12 Dec 22
Affimed Provides Updated Clinical Data from Phase 1/2 Study of
8:15am
6-K
v5knca iwtys
15 Nov 22
Current report (foreign)
6:42am
6-K
ozwr6hpw1
3 Nov 22
Affimed and Artiva Biotherapeutics Announce Partnership to Advance
9:23am
6-K
pgca1t1zb77sg9e
11 Aug 22
Current report (foreign)
6:31am
6-K
ydc 50k3zyza0t
23 Jun 22
Current report (foreign)
7:28am
6-K
fz4rg62
1 Jun 22
Current report (foreign)
6:53am
6-K
qmmf9nh
24 May 22
Affimed Announces Annual General Meeting of Shareholders
6:40am
6-K
05vzeso334dlbal
18 Apr 22
Current report (foreign)
4:06pm
424B5
y5dx1umrzm tu
14 Apr 22
Prospectus supplement for primary offering
4:17pm
424B5
noejtbwt
12 Apr 22
Prospectus supplement for primary offering
4:11pm
6-K
jptq0 zj25u7ypmi
11 Apr 22
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human
6:32am
EFFECT
z5j an8aeqvfp37s
7 Apr 22
Notice of effectiveness
12:15am
POS AM
pk3z28ge 8m
31 Mar 22
Prospectus update (post-effective amendment)
4:37pm
6-K
6y1lybnok91gm9ua7qj1
31 Mar 22
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
7:17am
POSASR
du7 m7stnx0y7n5d
31 Mar 22
Automatic shelf registration (post-effective amendment)
7:10am
6-K
etfwkk98br lvls4f
6 Jan 22
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022
7:23am
6-K
vwmiwc l3vceyt7
9 Dec 21
Current report (foreign)
7:30am
6-K
xal7ti
22 Nov 21
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate
7:55am